Tokyo Tape
Sign in
← GNI Group

Quarterly report · Q3

2160.TEDINET S100SA1Y
Period2023-01-01 → 2023-09-30
Filed2023-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥20.5bn2023-01-01 → 2023-09-30Cons.Revenue IFRS
Revenue¥6.5bn2023-07-01 → 2023-09-30dCons.Revenue IFRS
Revenue¥17.4bn2022-01-01 → 2022-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥12.8bn2022-01-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥4.6bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Operating income¥6.8bn2023-01-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income¥1.3bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income¥1.5bn2022-01-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥490m2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax¥6.4bn2023-01-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax¥1.3bn2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax¥768m2022-01-01 → 2022-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥1.2bn2022-01-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥433m2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥2.2bn2023-01-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥554m2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥389m2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥1.1bn2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥400m2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥4.8bn2023-01-01 → 2023-09-30Cons.Profit loss IFRS
Net income¥790m2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income−¥868m2022-01-01 → 2022-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥324m2022-01-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥126m2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥48.5bnat 2023-09-30Cons.Assets IFRS
Total assets¥33.9bnat 2022-12-31Cons.Assets IFRS
Total assets¥36.5bnat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥21.9bnat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥14.1bnat 2022-12-31Cons.Liabilities IFRS
Net assets / equity¥26.6bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥19.8bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥22.0bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥19.3bnat 2021-12-31dCons.Equity IFRS
Equity (owners)¥24.2bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥21.0bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥22.9bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥18.1bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.0bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥12.7bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥14.4bnat 2021-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥4.4bn2023-01-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥393m2022-01-01 → 2022-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥163m2022-01-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥3.7bn2023-01-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥4.1bn2022-01-01 → 2022-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥2.9bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥5.0bn2023-01-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥646m2022-01-01 → 2022-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥299m2022-01-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥46.612023-01-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥11.682023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥8.192022-01-01 → 2022-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥22.672022-01-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥8.422022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥46.132023-01-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥11.332023-07-01 → 2023-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥8.112022-01-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥22.462022-01-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥8.282022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio50.0%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio61.8%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio62.8%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-09-30−¥24m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-09-30−¥24m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue2023-01-01 → 2023-09-30¥2.3bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue external2023-01-01 → 2023-09-30¥2.3bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue intersegment2023-01-01 → 2023-09-30¥24m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentsegment profit2023-01-01 → 2023-09-30¥888m
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue2023-01-01 → 2023-09-30¥18.3bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue external2023-01-01 → 2023-09-30¥18.3bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentsegment profit2023-01-01 → 2023-09-30¥5.9bn
—segment totalrevenue2023-01-01 → 2023-09-30¥20.6bn
—segment totalrevenue external2023-01-01 → 2023-09-30¥20.5bn
—segment totalrevenue intersegment2023-01-01 → 2023-09-30¥24m
—segment totalsegment profit2023-01-01 → 2023-09-30¥6.8bn
Reconciling Itemsreconcilingrevenue2022-01-01 → 2022-09-30−¥38m
Reconciling Itemsreconcilingrevenue intersegment2022-01-01 → 2022-09-30−¥38m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue2022-01-01 → 2022-09-30¥1.8bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue external2022-01-01 → 2022-09-30¥1.7bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue intersegment2022-01-01 → 2022-09-30¥38m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentsegment profit2022-01-01 → 2022-09-30¥699m
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue2022-01-01 → 2022-09-30¥11.0bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue external2022-01-01 → 2022-09-30¥11.0bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentsegment profit2022-01-01 → 2022-09-30¥796m
—segment totalrevenue2022-01-01 → 2022-09-30¥12.8bn
—segment totalrevenue external2022-01-01 → 2022-09-30¥12.8bn
—segment totalrevenue intersegment2022-01-01 → 2022-09-30¥38m
—segment totalsegment profit2022-01-01 → 2022-09-30¥1.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 682
ItemContextValueUnit
Net decrease increase in time deposits inv cf IFRSPrior1YTDDuration-1159200000JPY
Net decrease increase in time deposits inv cf IFRSCurrentYTDDuration-1765800000JPY
Purchase of property plant and equipment inv cf IFRSPrior1YTDDuration-723140000JPY
Purchase of property plant and equipment inv cf IFRSCurrentYTDDuration-1041104000JPY
Proceeds from sale of property plant and equipment inv cf IFRSPrior1YTDDuration－JPY
Proceeds from sale of property plant and equipment inv cf IFRSCurrentYTDDuration1927000JPY
Purchase of intangible assets inv cf IFRSPrior1YTDDuration-441652000JPY
Purchase of intangible assets inv cf IFRSCurrentYTDDuration-694565000JPY
Purchase of investment securities inv cf IFRSPrior1YTDDuration-589252000JPY
Purchase of investment securities inv cf IFRSCurrentYTDDuration-139128000JPY
Increase of rent deposit inv cf IFRSPrior1YTDDuration-266000JPY
Increase of rent deposit inv cf IFRSCurrentYTDDuration-3753000JPY
Decrease of rent deposit inv cf IFRSPrior1YTDDuration449000JPY
Decrease of rent deposit inv cf IFRSCurrentYTDDuration－JPY
Payments for loans receivable inv cf IFRSPrior1YTDDuration－JPY
Payments for loans receivable inv cf IFRSCurrentYTDDuration-58860000JPY
Collection of loans receivable inv cf IFRSPrior1YTDDuration3557000JPY
Collection of loans receivable inv cf IFRSCurrentYTDDuration3557000JPY
Net cash provided by used in investing activities IFRSPrior1YTDDuration-2909505000JPY
Net cash provided by used in investing activities IFRSCurrentYTDDuration-3697727000JPY
Net increase decrease in short term borrowings fin cf IFRSPrior1YTDDuration-200000000JPY
Net increase decrease in short term borrowings fin cf IFRSCurrentYTDDuration1100000000JPY
Capital contribution from non controlling interests fin cf IFRSPrior1YTDDuration－JPY
Capital contribution from non controlling interests fin cf IFRSCurrentYTDDuration4008959000JPY
Proceeds from exercise of share acquisition rights fin cf IFRSPrior1YTDDuration－JPY
Proceeds from exercise of share acquisition rights fin cf IFRSCurrentYTDDuration27504000JPY
Proceeds from issuance of share acquisition rights fin cf IFRSPrior1YTDDuration－JPY
Proceeds from issuance of share acquisition rights fin cf IFRSCurrentYTDDuration357000JPY
Repayments of lease obligations fin cf IFRSPrior1YTDDuration-98520000JPY
Repayments of lease obligations fin cf IFRSCurrentYTDDuration-152451000JPY
Payments for purchase of treasury shares fin cf IFRSPrior1YTDDuration－JPY
Payments for purchase of treasury shares fin cf IFRSCurrentYTDDuration-38000JPY
Other fin cf IFRSPrior1YTDDuration-760000JPY
Other fin cf IFRSCurrentYTDDuration-2838000JPY
Net cash provided by used in financing activities IFRSPrior1YTDDuration-299280000JPY
Net cash provided by used in financing activities IFRSCurrentYTDDuration4981492000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1YTDDuration1741793000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSCurrentYTDDuration1366537000JPY
Net increase decrease in cash and cash equivalents IFRSPrior1YTDDuration-1629920000JPY
Net increase decrease in cash and cash equivalents IFRSCurrentYTDDuration7093291000JPY
Cash and cash equivalents IFRSPrior2YearInstant14352133000JPY
Cash and cash equivalents IFRSPrior1YearInstant11049310000JPY
Cash and cash equivalents IFRSPrior1QuarterInstant12722213000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant18142601000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q3r_E05712-000PharmaceuticalReportableSegmentMember11046069000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q3r_E05712-000MedicalDeviceReportableSegmentMember1714961000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReportableSegmentsMember12761031000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSPrior1YTDDuration12761031000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E05712-000PharmaceuticalReportableSegmentMember－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-12-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass